Liquidia (NASDAQ:LQDA) Raised to “Strong-Buy” at Lifesci Capital

Lifesci Capital upgraded shares of Liquidia (NASDAQ:LQDA) to a strong-buy rating in a report published on Wednesday morning, Zacks.com reports.

Several other research analysts have also weighed in on LQDA. HC Wainwright lowered their price objective on shares of Liquidia from $32.00 to $29.00 and set a buy rating on the stock in a research note on Tuesday, August 20th. Needham & Company LLC restated a buy rating and set a $25.00 price objective on shares of Liquidia in a research note on Monday, August 19th. Oppenheimer started coverage on shares of Liquidia in a research note on Tuesday, June 25th. They set a market perform rating on the stock. Bank of America lowered their price objective on shares of Liquidia from $24.00 to $23.00 and set a buy rating on the stock in a research note on Tuesday, August 20th. Finally, BTIG Research lowered their price objective on shares of Liquidia from $29.00 to $25.00 and set a buy rating on the stock in a research note on Monday, August 19th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Liquidia has a consensus rating of Moderate Buy and an average target price of $24.00.

Liquidia Trading Down 0.6 %

Shares of LQDA stock opened at $10.03 on Wednesday. Liquidia has a 1 year low of $5.71 and a 1 year high of $16.99. The firm’s fifty day moving average price is $10.44 and its two-hundred day moving average price is $12.24. The firm has a market capitalization of $766.43 million, a P/E ratio of -6.43 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. As a group, equities research analysts forecast that Liquidia will post -1.71 EPS for the current fiscal year.

Insider Buying and Selling

In other Liquidia news, CEO Roger Jeffs sold 8,053 shares of the business’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $100,904.09. Following the completion of the sale, the chief executive officer now owns 818,932 shares of the company’s stock, valued at $10,261,217.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Liquidia news, CFO Michael Kaseta sold 3,906 shares of the business’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $48,942.18. Following the completion of the sale, the chief financial officer now owns 312,389 shares of the company’s stock, valued at $3,914,234.17. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Roger Jeffs sold 8,053 shares of the business’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $100,904.09. Following the completion of the sale, the chief executive officer now directly owns 818,932 shares of the company’s stock, valued at $10,261,217.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,422 shares of company stock valued at $256,998. Company insiders own 31.60% of the company’s stock.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC bought a new stake in shares of Liquidia during the 2nd quarter worth approximately $27,000. Hilltop National Bank bought a new stake in shares of Liquidia during the 2nd quarter worth approximately $33,000. Deuterium Capital Management LLC bought a new stake in shares of Liquidia during the 2nd quarter worth approximately $120,000. DMC Group LLC bought a new stake in shares of Liquidia during the 2nd quarter worth approximately $122,000. Finally, Whitcomb & Hess Inc. bought a new stake in shares of Liquidia during the 2nd quarter worth approximately $126,000. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).